Abstract: Described is the antibacterial protein SBL200 with specific antibacterial activity against Streptococci. More specifically, described is Streptococcus-specific antibacterial protein SBL200, and a composition including the Streptococcus-specific antibacterial protein SBL200 as an active ingredient for the treatment of an infection caused by Streptococci, wherein the antibacterial protein retains ability to lyse Streptococci and possessing the amino acid sequence represented by SEQ ID NO: 1.

Abstract: Described is an antimicrobial protein SBL2200 having antimicrobial activity specific for Streptococci and, more specifically, to: a Streptococci-specific antimicrobial protein SBL2200 having the capacity to specifically lyse Streptococci and having an amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Streptococci, including the Streptococci-specific antimicrobial protein SBL2200 as an active ingredient.

Abstract: The present invention relates to an antibacterial protein SSL200 having a specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, the present invention relates to: an antibacterial protein SSL200 specific for Staphylococci including Staphylococcus aureus, the protein being characterized by having the ability to specifically lyse Staphylococci including Staphylococcus aureus and having an amino acid sequence represented by SEQ ID NO: 1; and a composition for treating infections caused by Staphylococci including Staphylococcus aureus, the composition comprising, as an active ingredient, the antibacterial protein SSL200 specific for Staphylococci including Staphylococcus aureus.

Abstract: Described is an antibacterial protein S2200 which has specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, described is antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus, which has the ability to specifically lyse Staphylococci including Staphylococcus aureus and has the amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Staphylococci including Staphylococcus aureus, containing as an active ingredient antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus.

Abstract: The present invention relates to an antibacterial protein CDL200 with an antibacterial activity specific against Clostridioides difficile. More specifically, the present invention relates to an antibacterial protein CDL200 specific to Clostridioides difficile that may infect and cause disease in animals including humans, the antibacterial protein CDL200 being characterized by having the ability to specifically lyse the Clostridioides difficile and containing the amino acid sequence represented by SEQ ID NO: 1. In addition, the present invention relates to a pharmaceutical composition for treating an infection or disease caused by Clostridioides difficile, the composition containing the antibacterial protein CDL200 specific to Clostridioides difficile as an active ingredient.

Abstract: An antibacterial protein against Bacillus with the amino acid sequence as set forth in SEQ ID NO: 1 is disclosed. Also disclosed is a method of preparing an antibacterial protein against Bacillus. The method includes: culturing BL21-pBAD-BAL200 cells, the BL21-pBAD-BAL200 cells including a plasmid that comprising a sequence as set forth in SEQ ID NO: 2; inducing the expression of the antibacterial protein; and purifying the antibacterial protein.

Abstract: Described is compound that can be used as an alternative to botulinum neurotoxin and a preparation method thereof, and more specifically, the present invention relates to a myricetin acetyl derivative and a preparation method thereof, wherein the myricetin acetyl derivative has significantly improved stability, including in-vivo stability, and has the ability to inhibit SNARE complex formation, and as a result, to inhibit acetylcholine release.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: The present invention is related to a mucosal mRNA vaccine. More specifically, the present invention relates to novel mucosal mRNA vaccine based on a peptide-conjugated, mRNA loaded nanoparticle with enhanced vaccine efficacy, and a method of preparing the same.

Abstract: A composition for treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage Esc-COP-23 having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.

Abstract: The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.

Abstract: The present invention relates to an intracellular expression enhancing genetic element, which enhances the intracellular expression of target protein encoded in RNA therapeutics such as mRNA vaccines and RNA medicines. In more detail, the present invention relates to the RNA molecule which has the genetic element capable of enhancing the intracellular expression of target protein encoded in RNA therapeutics delivered into cells; the plasmid used to synthesize the RNA molecule having the genetic element “E3”; the method for synthesizing RNA molecule having the genetic element “E3” using the plasmid and utilizing the synthesized RNA molecule as RNA therapeutics.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.

Abstract: A method for preparing a porcine myoglobin includes: constructing a first plasmid containing genes for heme biosynthesis pathway enzymes; constructing a second plasmid containing a gene for Sus scrofa myoglobin MYG; constructing a first Escherichia coli production host containing the first plasmid and the second plasmid; and producing the porcine myoglobin by culturing the first Escherichia coli production host. A composition useful as a meat flavor and/or an iron supplement includes the porcine myoglobin prepared in accordance with the method.

Abstract: A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.